Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08GVB
|
||||
| Former ID |
DNCL001730
|
||||
| Drug Name |
AMR-001
|
||||
| Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | ||
| Company |
Amorcyte; Progenitor Cell Therapy
|
||||
| Target and Pathway | |||||
| Target(s) | Hematopoietic progenitor cell antigen CD34 (CD34) | Target Info | Modulator | [2] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| WikiPathways | Hematopoietic Stem Cell Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01495364) NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health. | ||||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 743421). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.